aTyr announces Resolaris trial results

aTyr Pharma has released results of its exploratory clinical trials designed to evaluate the safety and potential activity of Resolaris in treating LGMD2B and FSHD.
The Phase 1b/2 LGMD2B/FSHD trial was conducted at six sites worldwide.
"Congratulations to our team, collaborators and patients that helped us accomplish the fundamental objectives for these clinical trials: (1) to demonstrate the safety and tolerability of our product candidate, Resolaris, across different RMICs and (2) to explore different readouts of potential clinical activity and product candidate activity in different RMICs," aTyr CEO John Mendlein said. "We are very pleased to see RMIC patients with two entirely different genetic etiologies showing improvement in muscle strength in three months as measured by manual muscle testing."
Mendlein said that taken together, the clinical data supports the potential of Resolaris as a single treatment for multiple rare myopathies with an immune component.
"We believe our clinical results will help inform and direct the future clinical development of Resolaris in RMICs," Mendlein said. 
Patients participating in the open-label, intra-patient, placebo run-in, dose escalation study received 12 weeks of treatment.